JAK2 and cancer: Previous data from our laboratory showed that small molecules targeting mTORC1 (RAD001) and mTORC2 (PP242) as single agents resulted in inhibitory acivity in several in-vitro cellular models and, when combined with JAK2 inhibitors, produced synergistic activity 39; however, a more profound inhibition of PI3K/Akt signalling may be required for an effective anti-cancer activity.